Clinical Trial Update: A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-3475-407/KEYNOTE-407 evaluated pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment for metastatic squamous non-sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• CARBOPLATIN (Carboplatin)
• KEYTRUDA (PEMBROLIZUMAB)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-04-10